Androgen excess: Investigations and management

Daria Lizneva, Larisa P Gavrilova-Jordan, Walidah Walker, Ricardo Azziz

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Androgen excess (AE) is a key feature of polycystic ovary syndrome (PCOS) and results in, or contributes to, the clinical phenotype of these patients. Although AE will contribute to the ovulatory and menstrual dysfunction of these patients, the most recognizable sign of AE includes hirsutism, acne, and androgenic alopecia or female pattern hair loss (FPHL). Evaluation includes not only scoring facial and body terminal hair growth using the modified Ferriman–Gallwey method but also recording and possibly scoring acne and alopecia. Moreover, assessment of biochemical hyperandrogenism is necessary, particularly in patients with unclear or absent hirsutism, and will include assessing total and free testosterone (T), and possibly dehydroepiandrosterone sulfate (DHEAS) and androstenedione, although these latter contribute limitedly to the diagnosis. Assessment of T requires use of the highest quality assays available, generally radioimmunoassays with extraction and chromatography or mass spectrometry preceded by liquid or gas chromatography. Management of clinical hyperandrogenism involves primarily either androgen suppression, with a hormonal combination contraceptive, or androgen blockade, as with an androgen receptor blocker or a 5α-reductase inhibitor, or a combination of the two. Medical treatment should be combined with cosmetic treatment including topical eflornithine hydrochloride and short-term (shaving, chemical depilation, plucking, threading, waxing, and bleaching) and long-term (electrolysis, laser therapy, and intense pulse light therapy) cosmetic treatments. Generally, acne responds to therapy relatively rapidly, whereas hirsutism is slower to respond, with improvements observed as early as 3 months, but routinely only after 6 or 8 months of therapy. Finally, FPHL is the slowest to respond to therapy, if it will at all, and it may take 12 to 18 months of therapy for an observable response.

Original languageEnglish (US)
Pages (from-to)98-118
Number of pages21
JournalBest Practice and Research: Clinical Obstetrics and Gynaecology
Volume37
DOIs
StatePublished - Nov 1 2016

Fingerprint

Androgens
Alopecia
Hirsutism
Acne Vulgaris
Hyperandrogenism
Therapeutics
Hair Removal
Eflornithine
Electrolysis
Dehydroepiandrosterone Sulfate
Phototherapy
Androstenedione
Polycystic Ovary Syndrome
Androgen Receptors
Laser Therapy
Contraceptive Agents
Cosmetics
Gas Chromatography
Hair
Radioimmunoassay

Keywords

  • acne
  • female pattern hair loss
  • hirsutism
  • hyperandrogenism
  • PCOS

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Androgen excess : Investigations and management. / Lizneva, Daria; Gavrilova-Jordan, Larisa P; Walker, Walidah; Azziz, Ricardo.

In: Best Practice and Research: Clinical Obstetrics and Gynaecology, Vol. 37, 01.11.2016, p. 98-118.

Research output: Contribution to journalReview article

@article{f4ddd67262c646568df90815170dd709,
title = "Androgen excess: Investigations and management",
abstract = "Androgen excess (AE) is a key feature of polycystic ovary syndrome (PCOS) and results in, or contributes to, the clinical phenotype of these patients. Although AE will contribute to the ovulatory and menstrual dysfunction of these patients, the most recognizable sign of AE includes hirsutism, acne, and androgenic alopecia or female pattern hair loss (FPHL). Evaluation includes not only scoring facial and body terminal hair growth using the modified Ferriman–Gallwey method but also recording and possibly scoring acne and alopecia. Moreover, assessment of biochemical hyperandrogenism is necessary, particularly in patients with unclear or absent hirsutism, and will include assessing total and free testosterone (T), and possibly dehydroepiandrosterone sulfate (DHEAS) and androstenedione, although these latter contribute limitedly to the diagnosis. Assessment of T requires use of the highest quality assays available, generally radioimmunoassays with extraction and chromatography or mass spectrometry preceded by liquid or gas chromatography. Management of clinical hyperandrogenism involves primarily either androgen suppression, with a hormonal combination contraceptive, or androgen blockade, as with an androgen receptor blocker or a 5α-reductase inhibitor, or a combination of the two. Medical treatment should be combined with cosmetic treatment including topical eflornithine hydrochloride and short-term (shaving, chemical depilation, plucking, threading, waxing, and bleaching) and long-term (electrolysis, laser therapy, and intense pulse light therapy) cosmetic treatments. Generally, acne responds to therapy relatively rapidly, whereas hirsutism is slower to respond, with improvements observed as early as 3 months, but routinely only after 6 or 8 months of therapy. Finally, FPHL is the slowest to respond to therapy, if it will at all, and it may take 12 to 18 months of therapy for an observable response.",
keywords = "acne, female pattern hair loss, hirsutism, hyperandrogenism, PCOS",
author = "Daria Lizneva and Gavrilova-Jordan, {Larisa P} and Walidah Walker and Ricardo Azziz",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.bpobgyn.2016.05.003",
language = "English (US)",
volume = "37",
pages = "98--118",
journal = "Best Practice and Research in Clinical Obstetrics and Gynaecology",
issn = "1521-6934",
publisher = "Bailliere Tindall Ltd",

}

TY - JOUR

T1 - Androgen excess

T2 - Investigations and management

AU - Lizneva, Daria

AU - Gavrilova-Jordan, Larisa P

AU - Walker, Walidah

AU - Azziz, Ricardo

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Androgen excess (AE) is a key feature of polycystic ovary syndrome (PCOS) and results in, or contributes to, the clinical phenotype of these patients. Although AE will contribute to the ovulatory and menstrual dysfunction of these patients, the most recognizable sign of AE includes hirsutism, acne, and androgenic alopecia or female pattern hair loss (FPHL). Evaluation includes not only scoring facial and body terminal hair growth using the modified Ferriman–Gallwey method but also recording and possibly scoring acne and alopecia. Moreover, assessment of biochemical hyperandrogenism is necessary, particularly in patients with unclear or absent hirsutism, and will include assessing total and free testosterone (T), and possibly dehydroepiandrosterone sulfate (DHEAS) and androstenedione, although these latter contribute limitedly to the diagnosis. Assessment of T requires use of the highest quality assays available, generally radioimmunoassays with extraction and chromatography or mass spectrometry preceded by liquid or gas chromatography. Management of clinical hyperandrogenism involves primarily either androgen suppression, with a hormonal combination contraceptive, or androgen blockade, as with an androgen receptor blocker or a 5α-reductase inhibitor, or a combination of the two. Medical treatment should be combined with cosmetic treatment including topical eflornithine hydrochloride and short-term (shaving, chemical depilation, plucking, threading, waxing, and bleaching) and long-term (electrolysis, laser therapy, and intense pulse light therapy) cosmetic treatments. Generally, acne responds to therapy relatively rapidly, whereas hirsutism is slower to respond, with improvements observed as early as 3 months, but routinely only after 6 or 8 months of therapy. Finally, FPHL is the slowest to respond to therapy, if it will at all, and it may take 12 to 18 months of therapy for an observable response.

AB - Androgen excess (AE) is a key feature of polycystic ovary syndrome (PCOS) and results in, or contributes to, the clinical phenotype of these patients. Although AE will contribute to the ovulatory and menstrual dysfunction of these patients, the most recognizable sign of AE includes hirsutism, acne, and androgenic alopecia or female pattern hair loss (FPHL). Evaluation includes not only scoring facial and body terminal hair growth using the modified Ferriman–Gallwey method but also recording and possibly scoring acne and alopecia. Moreover, assessment of biochemical hyperandrogenism is necessary, particularly in patients with unclear or absent hirsutism, and will include assessing total and free testosterone (T), and possibly dehydroepiandrosterone sulfate (DHEAS) and androstenedione, although these latter contribute limitedly to the diagnosis. Assessment of T requires use of the highest quality assays available, generally radioimmunoassays with extraction and chromatography or mass spectrometry preceded by liquid or gas chromatography. Management of clinical hyperandrogenism involves primarily either androgen suppression, with a hormonal combination contraceptive, or androgen blockade, as with an androgen receptor blocker or a 5α-reductase inhibitor, or a combination of the two. Medical treatment should be combined with cosmetic treatment including topical eflornithine hydrochloride and short-term (shaving, chemical depilation, plucking, threading, waxing, and bleaching) and long-term (electrolysis, laser therapy, and intense pulse light therapy) cosmetic treatments. Generally, acne responds to therapy relatively rapidly, whereas hirsutism is slower to respond, with improvements observed as early as 3 months, but routinely only after 6 or 8 months of therapy. Finally, FPHL is the slowest to respond to therapy, if it will at all, and it may take 12 to 18 months of therapy for an observable response.

KW - acne

KW - female pattern hair loss

KW - hirsutism

KW - hyperandrogenism

KW - PCOS

UR - http://www.scopus.com/inward/record.url?scp=84997824522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997824522&partnerID=8YFLogxK

U2 - 10.1016/j.bpobgyn.2016.05.003

DO - 10.1016/j.bpobgyn.2016.05.003

M3 - Review article

C2 - 27387253

AN - SCOPUS:84997824522

VL - 37

SP - 98

EP - 118

JO - Best Practice and Research in Clinical Obstetrics and Gynaecology

JF - Best Practice and Research in Clinical Obstetrics and Gynaecology

SN - 1521-6934

ER -